文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

埃塞俄比亚HIV合并内脏利什曼病患者抗利什曼药物暴露偏低

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

埃塞俄比亚队列研究评估HIV-VL共感染患者抗利什曼药物及抗逆转录病毒药物暴露。LAmB单药或联合米替福星治疗时,两性霉素B Cmax较非VL患者低约2倍,米替福星暴露较东非成人VL患者低35%,部分由剂量低19%解释,提示可能需调整剂量。

要点

  • HIV-VL共感染者抗利什曼药物暴露偏低
  • 两性霉素B Cmax较非VL患者低约2倍
  • 米替福星暴露低35%,部分因剂量低19%

核心结论

  • 该HIV-VL共感染队列中抗利什曼药物暴露偏低。
  • 两性霉素B Cmax较既往非VL患者低2倍。
  • 米替福星暴露较东非成人VL患者低35%,仅部分由剂量低19%解释,可能需调整剂量。
  • 鉴于复发比例高,确保充分药物暴露尤为重要。

研究设计与样本

  • 埃塞俄比亚队列研究,纳入HIV-VL共感染患者。
  • 患者接受LAmB单药(总剂量40 mg/kg,24天)或LAmB(总剂量30 mg/kg,11天)联合米替福星(100 mg/天,28天),可延长一周期。
  • 用LC-MS/MS测定干血斑或血浆中米替福星、总两性霉素B及ARV浓度。

主要发现

  • 第1天两性霉素B Cmax中位数(IQR)为24.6 μg/mL(17.0-34.9 μg/mL)。
  • 联合治疗最后一天两性霉素B Cmax为40.9 μg/mL(25.4-53.1 μg/mL),单药最后一天为33.2 μg/mL(29.0-46.6 μg/mL)。
  • 第28天米替福星浓度为18.7 μg/mL(15.4-22.5 μg/mL)。
  • 米替福星暴露与两性霉素B蓄积相关。
  • 抗利什曼治疗期间ARV浓度总体稳定,但许多患者依非韦伦Cmin低于1 μg/mL治疗目标。

关键数值与推荐

  • LAmB单药总剂量40 mg/kg over 24天。
  • 联合方案LAmB总剂量30 mg/kg over 11天加米替福星100 mg/day共28天。
  • 两性霉素B Cmax较非VL患者低2倍。
  • 米替福星暴露较东非成人VL患者低35%,仅部分由剂量低19%解释。
  • 依非韦伦Cmin治疗目标为1 μg/mL。

临床怎么用

  • HIV-VL共感染者使用LAmB和米替福星时需关注药物暴露不足。
  • 米替福星可能需要剂量调整以达充分暴露。
  • 监测依非韦伦Cmin,许多患者低于1 μg/mL治疗目标。
  • 鉴于复发比例高,应确保抗利什曼药物充分暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial and antiretroviral (ARV) drugs is still unknown. METHODS: HIV-VL co-infected patients received the recommended liposomal amphotericin B (LAmB) monotherapy (total dose 40 mg/kg over 24 days) or combination therapy of LAmB (total dose 30 mg/kg over 11 days) plus 28 days 100 mg/day miltefosine, with possibility to extend treatment for another cycle. Miltefosine, total amphotericin B and ARV concentrations were determined in dried blood spots or plasma using LC-MS/MS. RESULTS: Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively. Day 28 miltefosine concentration was 18.7 (15.4-22.5) μg/mL. Miltefosine exposure correlated with amphotericin B accumulation. ARV concentrations were generally stable during antileishmanial treatment, although efavirenz Cmin was below the 1 μg/mL therapeutic target for many patients. CONCLUSIONS: This study demonstrates that antileishmanial drug exposure was low in this cohort of HIV co-infected VL patients. Amphotericin B Cmax was 2-fold lower than previously observed in non-VL patients. Miltefosine exposure in HIV-VL co-infected patients was 35% lower compared with adult VL patients in Eastern Africa, only partially explained by a 19% lower dose, possibly warranting a dose adjustment. Adequate drug exposure in these HIV-VL co-infected patients is especially important given the high proportion of relapses.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kip AE, Blesson S, Alves F, et al. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. J Antimicrob Chemother. 2021. PMID: 33677546. doi:10.1093/jac/dkab013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。